
Global Oral Proteins and Peptides Market Report and Forecast 2024-2032
Description
Global Oral Proteins and Peptides Market Report and Forecast 2024-2032
Global Oral Proteins and Peptides Market Report and Forecast 2024-2032
Global Oral Proteins and Peptides Market Outlook
The global oral proteins and peptides market size was valued at USD 2.52 billion in 2023, driven by increasing prevalence of diabetes and gastrointestinal disorders across the globe. The market size is anticipated to grow at a CAGR of 14.5 % during the forecast period of 2024-2032 to achieve a value of USD 8.3 billion by 2032.
Oral Proteins and Peptides: Introduction
The Oral Proteins and Peptides market involves the development and distribution of protein and peptide-based therapeutics designed for oral administration. These biomolecules offer potential treatments for various diseases, including diabetes, gastrointestinal disorders, and others. Oral delivery is preferred for its convenience and non-invasive nature but poses challenges due to protein and peptide degradation in the digestive system. Advances in drug formulation and delivery technologies aim to overcome these barriers, enhancing bioavailability and therapeutic effectiveness.
Key Trends in the Global Oral Proteins and Peptides Market
Efforts are being intensified to develop efficient delivery mechanisms to protect proteins and peptides from digestive enzymes and improve absorption in the gastrointestinal tract. Technologies like nanoparticle encapsulation and permeability enhancers are gaining traction.
Initially concentrated in areas like diabetes and gastrointestinal disorders, the scope of oral proteins and peptides is broadening to include a wider range of therapeutic areas, including autoimmune diseases and cancers.
The convenience and non-invasive nature of oral administration are in line with the increasing demand for patient-centric treatment options, driving research and acceptance of oral proteins and peptides.
Pharmaceutical companies are increasingly collaborating with biotech firms and academic institutions to leverage expertise in drug development and commercialization, accelerating the introduction of innovative products.
Regulatory bodies are acknowledging the potential of oral proteins and peptides, leading to streamlined pathways for approval, especially for treatments addressing unmet medical needs.
The ease of administration and storage of oral formulations align with global health goals to improve access to essential medicines, particularly in low-resource settings.
Global Oral Proteins and Peptides Market Segmentation
Market Breakup by Drug Type
- Plecanatide
- Linaclotide
- Octreotide
- Calcitonin
- Insulin
- Gastric and Digestive Disorders
- Bone Diseases
- Diabetes
- Hormonal Disorders
- Hospitals
- Ambulatory Surgical Centre
- Clinics
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
In North America, the oral proteins and peptides market is propelled by advanced biotechnological research, a strong pharmaceutical industry, and substantial healthcare spending. The region leads in innovative drug delivery system developments and patient-centric drug design, focusing on improving the bioavailability and efficacy of oral protein and peptide therapeutics. There's also a significant emphasis on regulatory compliance and intellectual property rights, fostering a competitive and dynamic market environment.
Europe's market benefits from a robust healthcare research infrastructure, stringent regulatory standards, and a focus on advanced pharmaceutical innovation. The region shows a strong commitment to developing novel drug delivery technologies, including oral proteins and peptides. Collaborative research efforts, supported by public and private funding, contribute to the exploration of new treatments for chronic diseases. The market is also influenced by policies aimed at ensuring patient safety and high-quality pharmaceutical products.
The market in the Asia-Pacific region is rapidly growing, driven by increasing healthcare investments, a rising prevalence of chronic diseases, and improvements in biopharmaceutical research capabilities. Countries like China, India, and Japan are becoming significant players in the pharmaceutical industry, focusing on both innovative research and the production of generic drugs. The market's growth is further fueled by a growing middle class, increasing healthcare awareness, and expanding access to healthcare services.
Global Oral Proteins and Peptides Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players.
- Novo Nordisk A/S
- Synergy Pharmaceuticals Inc.
- Chiasma Inc.
- Tarsa Therapeutics Inc.
- Biocon Limited
- Generex Biotechnology Corp.
- AstraZeneca PLC
- Proxima Concepts Limited
- Oramed Pharmaceuticals Inc.
- Allergan Plc.
- Generex Biotechnology Corp.
- Hoffmann-La Roche
- Sanofi
- Bristol-Myers Squibb Company
- Hovione
Table of Contents
160 Pages
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Global Oral Proteins and Peptides Market Overview
- 3.1 Global Oral Proteins and Peptides Market Historical Value (2017-2023)
- 3.2 Global Oral Proteins and Peptides Market Forecast Value (2024-2031)
- 4 Global Oral Proteins and Peptides Market Landscape
- 4.1 Global Oral Proteins and Peptides Developers Landscape
- 4.1.1 Analysis by Year of Establishment
- 4.1.2 Analysis by Company Size
- 4.1.3 Analysis by Region
- 4.2 Global Oral Proteins and Peptides Product Landscape
- 4.2.1 Analysis by Type
- 4.2.2 Analysis by Products
- 5 Global Oral Proteins and Peptides Market Dynamics
- 5.1 Market Drivers and Constraints
- 5.2 SWOT Analysis
- 5.3 Porter’s Five Forces Model
- 5.4 Key Demand Indicators
- 5.5 Key Price Indicators
- 5.6 Industry Events, Initiatives, and Trends
- 5.7 Value Chain Analysis`
- 6 Global Oral Proteins and Peptides Market Segmentation
- 6.1 Global Oral Proteins and Peptides Market by Drug Type
- 6.1.1 Market Overview
- 6.1.2 Plecanatide
- 6.1.3 Linaclotide
- 6.1.4 Octreotide
- 6.1.5 Calcitonin
- 6.1.6 Insulin
- 6.2 Global Oral Proteins and Peptides Market by Application
- 6.2.1 Market Overview
- 6.2.2 Gastric and Digestive Disorders
- 6.2.3 Bone Diseases
- 6.2.4 Diabetes
- 6.2.5 Hormonal Disorders
- 6.3 Global Oral Proteins and Peptides Market by End User
- 6.3.1 Market Overview
- 6.3.2 Hospitals
- 6.3.3 Ambulatory Surgical Centre
- 6.3.4 Clinics
- 6.4 Global Oral Proteins and Peptides Market by Region
- 6.4.1 Market Overview
- 6.4.2 North America
- 6.4.3 Europe
- 6.4.4 Asia Pacific
- 6.4.5 Latin America
- 6.4.6 Middle East and Africa
- 7 North America Oral Proteins and Peptides Market
- 7.1 Market Share by Country
- 7.2 United States of America
- 7.3 Canada
- 8 Europe Oral Proteins and Peptides Market
- 8.1 Market Share by Country
- 8.2 United Kingdom
- 8.3 Germany
- 8.4 France
- 8.5 Italy
- 8.6 Others
- 9 Asia Pacific Oral Proteins and Peptides Market
- 9.1 Market Share by Country
- 9.2 China
- 9.3 Japan
- 9.4 India
- 1.1 ASEAN
- 9.5 Others
- 10 Latin America Oral Proteins and Peptides Market
- 10.1 Market Share by Country
- 10.2 Brazil
- 10.3 Argentina
- 10.4 Mexico
- 10.5 Others
- 11 Middle East and Africa Oral Proteins and Peptides Market
- 11.1 Market Share by Country
- 11.2 Saudi Arabia
- 11.3 United Arab Emirates
- 11.4 Nigeria
- 11.5 South Africa
- 11.6 Others
- 12 Patent Analysis
- 12.1 Analysis by Type of Patent
- 12.2 Analysis by Publication year
- 12.3 Analysis by Issuing Authority
- 12.4 Analysis by Patent Age
- 12.5 Analysis by CPC Analysis
- 12.6 Analysis by Patent Valuation
- 12.7 Analysis by Key Players
- 13 Grants Analysis
- 13.1 Analysis by year
- 13.2 Analysis by Amount Awarded
- 13.3 Analysis by Issuing Authority
- 13.4 Analysis by Grant Application
- 13.5 Analysis by Funding Institute
- 13.6 Analysis by NIH Departments
- 13.7 Analysis by Recipient Organization
- 14 Clinical Trials Analysis
- 14.1 Analysis by Trial Registration Year
- 14.2 Analysis by Trial Status
- 14.3 Analysis by Trial Phase
- 14.4 Analysis by Therapeutic Area
- 14.5 Analysis by Geography
- 15 Funding Analysis
- 15.1 Analysis by Funding Instances
- 15.2 Analysis by Type of Funding
- 15.3 Analysis by Funding Amount
- 15.4 Analysis by Leading Players
- 15.5 Analysis by Leading Investors
- 15.6 Analysis by Geography
- 16 Partnership and Collaborations Analysis
- 16.1 Analysis by Partnership Instances
- 16.2 Analysis by Type of Partnership
- 16.3 Analysis by Leading Players
- 16.4 Analysis by Geography
- 17 Supplier Landscape
- 17.1 Novo Nordisk A/S
- 17.1.1 Financial Analysis
- 17.1.2 Product Portfolio
- 17.1.3 Demographic Reach and Achievements
- 17.1.4 Mergers and Acquisition
- 17.1.5 Certifications
- 17.2 Synergy Pharmaceuticals Inc.
- 17.2.1 Financial Analysis
- 17.2.2 Product Portfolio
- 17.2.3 Demographic Reach and Achievements
- 17.2.4 Mergers and Acquisition
- 17.2.5 Certifications
- 17.3 Chiasma Inc.
- 17.3.1 Financial Analysis
- 17.3.2 Product Portfolio
- 17.3.3 Demographic Reach and Achievements
- 17.3.4 Mergers and Acquisition
- 17.3.5 Certifications
- 17.4 Tarsa Therapeutics Inc.
- 17.4.1 Financial Analysis
- 17.4.2 Product Portfolio
- 17.4.3 Demographic Reach and Achievements
- 17.4.4 Mergers and Acquisition
- 17.4.5 Certifications
- 17.5 Biocon Limited
- 17.5.1 Financial Analysis
- 17.5.2 Product Portfolio
- 17.5.3 Demographic Reach and Achievements
- 17.5.4 Mergers and Acquisition
- 17.5.5 Certifications
- 17.6 Generex Biotechnology Corp.
- 17.6.1 Financial Analysis
- 17.6.2 Product Portfolio
- 17.6.3 Demographic Reach and Achievements
- 17.6.4 Mergers and Acquisition
- 17.6.5 Certifications
- 17.7 AstraZeneca PLC
- 17.7.1 Financial Analysis
- 17.7.2 Product Portfolio
- 17.7.3 Demographic Reach and Achievements
- 17.7.4 Mergers and Acquisition
- 17.7.5 Certifications
- 17.8 Proxima Concepts Limited
- 17.8.1 Financial Analysis
- 17.8.2 Product Portfolio
- 17.8.3 Demographic Reach and Achievements
- 17.8.4 Mergers and Acquisition
- 17.8.5 Certifications
- 17.9 Oramed Pharmaceuticals Inc.
- 17.9.1 Financial Analysis
- 17.9.2 Product Portfolio
- 17.9.3 Demographic Reach and Achievements
- 17.9.4 Mergers and Acquisition
- 17.9.5 Certifications
- 17.10 Allergan Plc.
- 17.10.1 Financial Analysis
- 17.10.2 Product Portfolio
- 17.10.3 Demographic Reach and Achievements
- 17.10.4 Mergers and Acquisition
- 17.10.5 Certifications
- 17.11 Generex Biotechnology Corp.
- 17.11.1 Financial Analysis
- 17.11.2 Product Portfolio
- 17.11.3 Demographic Reach and Achievements
- 17.11.4 Mergers and Acquisition
- 17.11.5 Certifications
- 17.12 Hoffmann-La Roche
- 17.12.1 Financial Analysis
- 17.12.2 Product Portfolio
- 17.12.3 Demographic Reach and Achievements
- 17.12.4 Mergers and Acquisition
- 17.12.5 Certifications
- 17.13 Sanofi
- 17.13.1 Financial Analysis
- 17.13.2 Product Portfolio
- 17.13.3 Demographic Reach and Achievements
- 17.13.4 Mergers and Acquisition
- 17.13.5 Certifications
- 17.14 Bristol-Myers Squibb Company
- 17.14.1 Financial Analysis
- 17.14.2 Product Portfolio
- 17.14.3 Demographic Reach and Achievements
- 17.14.4 Mergers and Acquisition
- 17.14.5 Certifications
- 17.15 Hovione
- 17.15.1 Financial Analysis
- 17.15.2 Product Portfolio
- 17.15.3 Demographic Reach and Achievements
- 17.15.4 Mergers and Acquisition
- 17.15.5 Certifications
- 18 Global Oral Proteins and Peptides Market - Distribution Model (Additional Insight)
- 18.1 Overview
- 18.2 Potential Distributors
- 18.3 Key Parameters for Distribution Partner Assessment
- 19 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 20 Company Competitiveness Analysis (Additional Insight)
- 20.1 Very Small Companies
- 20.2 Small Companies
- 20.3 Mid-Sized Companies
- 20.4 Large Companies
- 20.5 Very Large Companies
- 21 Payment Methods (Additional Insight)
- 21.1 Government Funded
- 21.2 Private Insurance
- 21.3 Out-of-Pocket
- *Additional insights provided are customisable as per client requirements.
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.